• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

FDA fast tracks drugs for Ebola and Marburg viruses

Article

FDA has granted fast-track designation for the development of AVI-7288 and AVI-7537 (Sarepta Therapeutics), for the treatment of Marburg virus and Ebola virus, respectively.

FDA has granted fast-track designation for the development of AVI-7288 and AVI-7537 (Marburg hemorrhagic fever is a severe and potentially fatal disease in humans first recognized in 1967. It is caused by an RNA virus of the Filoviridae family and is understood to be endemic to Africa. The Marburg virus is classified as a Category A bioterrorism agent by the CDC, and was determined to pose a material threat to national security and public health by the Secretary of Homeland Security in 2006. Onset of the disease is often sudden, and the symptoms include fever, chills, nausea, vomiting, chest pain, and diarrhea. Increasingly severe symptoms may also include massive hemorrhaging and multiple organ dysfunctions. There are currently no treatments for Marburg virus infection beyond supportive care.The hemorrhagic fever caused by the Ebola virus is severe and often fatal in humans. The disease was first recognized in 1976 and is one of 2 members of a family of RNA viruses called Filoviridae. The disease is generally understood to be endemic to parts of Africa. Onset of illness from Ebola virus is abrupt with symptoms that include fever, headache, muscle ache, vomiting, and stomach pain. Internal and external bleeding may also be observed in some patients. There are currently no treatments for Ebola virus infection beyond supportive care and the mortality rate is very high.

Related Videos
Related Content
FDA Approves Bladder Cancer Immunotherapy

FDA Approves Bladder Cancer Immunotherapy

April 23rd 2024
Article

ImmunityBio’s Anktiva is an antibody cytokine fusion protein approved to treat patients with non-muscle invasive bladder cancer.

FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa

FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa

April 22nd 2024
Article

Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.

Par Recalls More Treprostinil Due to Silicone in the Product

Par Recalls More Treprostinil Due to Silicone in the Product

April 22nd 2024
Article

An additional seven lots of Treprostinil are affected on top of last month’s recall of one lot.

FDA Approves Pen Form of Entyvio for Crohn’s Disease

FDA Approves Pen Form of Entyvio for Crohn’s Disease

April 19th 2024
Article

Entyvio as an injection and subcutaneous formulations is approved to treat both Crohn’s and ulcerative colitis.

Site Logo

FDA Approves Stelara Biosimilar, Selarsdi

April 18th 2024
Article

Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.

Site Logo

Most Cancer Drugs With Accelerated Approval Don’t Show Benefit

April 18th 2024
Article

Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.

© 2024 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact